Trial Profile
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality When Initiated Early After Hospitalization for Acute Decompensated Heart Failure - ASTRONAUT
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary)
- Indications Decompensated heart failure
- Focus Registrational; Therapeutic Use
- Acronyms ASTRONAUT
- Sponsors Novartis; Novartis Pharmaceuticals
- 12 Mar 2018 Results reporting hyperkalemia (n=1,549) after hospitalization presented at the 67th Annual Scientific Session of the American College of Cardiology
- 16 Nov 2017 Results assessing clinical outcomes, plasma renin activity published in the European Journal of Heart Failure.
- 15 Nov 2017 Results of pre-specified neurohormonal substudy, presented at the 90th Annual Scientific Sessions of the American Heart Association.